 |
41 Diseases |  |
16 Trials |
|
16 Trials |  |
501 News |  |
| «12345678» |
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Prognostic factors for progression-free survival (PFS) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study () - Mar 4, 2022 - Abstract #ENETS2022ENETS_28;
P3
SPINET suggests LAN 120 mg could be an appropriate treatment for patients with SSTR positive BP-NETs. Positive prognostic factors were LAN treatment, TC subtype and absence of hepatic tumor load.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Clinical, Journal: External validity of somatostatin analogues trials in advanced neuroendocrine neoplasms: the GETNE-TRASGU study. (Pubmed Central) - Feb 22, 2022
Our results indicate that both octreotide LAR and lanreotide autogel had a similar effect on PFS. Consequently, both represent valid alternatives in patients with well-differentiated, metastatic GEP-NENs.
- | Journal: The future of somatostatin receptor ligands in acromegaly. (Pubmed Central) - Feb 19, 2022
Pasireotide, a second-generation SRL, shows higher efficacy with respect to both biochemical control and tumor shrinkage but has a worse safety profile...New formulations of available SRLs, such as oral, subcutaneous depot and nasal octreotide, may improve patients' adherence to treatment and quality of life since there will be more options available that better suit each patient. Finally, new drugs, such as paltusotine, somatropin, ONO-5788 and ONO-ST-468, may improve treatment adherence and present higher efficacy than currently available drugs.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, Journal: Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly. (Pubmed Central) - Feb 11, 2022
P2a
Lanreotide PRF was well tolerated and the pharmacokinetic profile suggests that a dosing interval of 12 weeks could be achievable. www.clinicaltrials.gov identifier is NCT02396953; EudraCT 2014-002389-62.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
PK/PD data, Journal: Bioanalysis of lanreotide in dog plasma using liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study of beagle dogs after single subcutaneous injection. (Pubmed Central) - Feb 4, 2022
This novel quantification method using UPLC-MS/MS was successfully applied to the pharmacokinetic analysis of lanreotide in dog plasma. The results will assist future studies of drug formulation and repurposing.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, P2 data, Journal: Efficacy and Safety of Lanreotide Autogel in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction: A Prospective Phase II Study. (Pubmed Central) - Jan 29, 2022
P2
The safety profile of LAN 120 mg was similar to that reported in other indications. ClinicalTrials.gov identifier: NCT02275338.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: Antiproliferative Effect Of Above-Label Doses Of Somatostatin Analogs For The Management Of Gastroenteropancreatic Neuroendocrine Tumors. (Pubmed Central) - Jan 27, 2022
Above-label doses of SSAs may offer a considerable prolongation in PFS and could be utilized as a bridge to other more toxic treatments. Patients with small bowel/colorectal primaries, Ki-67<5% and absence of/limited extrahepatic metastases are more likely to benefit from this approach.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, Observational data, Journal: Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria. (Pubmed Central) - Jan 15, 2022
P=N/A
Our study reflects routine lanreotide autogel use in patients with advanced/metastatic neuroendocrine tumors. This analysis shows effectiveness with stabilization of disease-related symptoms and good tolerability of lanreotide autogel in clinical practice.
- | metformin / Generic mfg.
Retrospective data, Journal: Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study. (Pubmed Central) - Jan 12, 2022
Lanreotide efficacy was confirmed in patients with advanced enteropancreatic NETs, regardless of diabetic status; DM was not a negative prognostic factor. A potential antitumor effect of metformin was observed in patients receiving placebo.
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, P3 data, Journal: Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan. (Pubmed Central) - Jan 7, 2022
The common adverse events were gastrointestinal disorders (12/13 patients) and administration site reactions (5/13 patients). Lanreotide autogel may be effective for controlling thyroid function and reducing the pituitary tumor size, and is tolerable in patients with TSHoma (Japic Clinical Trials Information; JapicCTI-173772).
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Clinical, Clinical data, Journal: Self-Administration of Long-Acting Somatostatin Analogues in NET Patients-Does It Affect the Clinical Outcome? (Pubmed Central) - Dec 27, 2021
The method of administration of long-acting SSA injection performed by professional medical staff vs. self-injection of the drug may significantly affect the risk of NET progression. The unequivocal confirmation of such a relationship requires further observation.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, P2 data, Clinical Trial,Phase II, Journal: Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. (Pubmed Central) - Dec 16, 2021
In patients with progressive NETs following standard-regimen LAN, reducing the dosing interval to every 14 days provided encouraging PFS, particularly in patients with a Ki-67 ≤ 10% (post hoc); no safety concerns and no deterioration in QoL were observed. Increasing LAN dosing frequency could therefore be considered before escalation to less well-tolerated therapies.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed, Metastases: PALACE: Study to Assess the Efficacy and Safety of Lanreotide Autogel (clinicaltrials.gov) - Dec 10, 2021
P3, N=43, Active, not recruiting, Sponsor: Ipsen
Increasing LAN dosing frequency could therefore be considered before escalation to less well-tolerated therapies. Recruiting --> Active, not recruiting
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion date, Trial primary completion date, HEOR: PREF-NET: United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting (clinicaltrials.gov) - Dec 8, 2021
P=N/A, N=100, Recruiting, Sponsor: Ipsen
Recruiting --> Active, not recruiting Trial completion date: Nov 2021 --> Feb 2022 | Trial primary completion date: Nov 2021 --> Feb 2022
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, P2 data, Journal: Long-term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open-label extension study. (Pubmed Central) - Nov 29, 2021
Lanreotide treatment had an acceptable safety profile and was effective over long-term treatment in Japanese patients with neuroendocrine tumors. No unexpected serious adverse events developed during prolonged use of lanreotide.
- ||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical: Lanreotide autogel/depot administered at 120 mg every 28 days may be an appropriate treatment for patients with advanced bronchopulmonary neuroendocrine tumors. @DianeReidyLagun @sloan_kettering @NANETS1 #NANETSGoesVirtual2021 #NANETS2021 https://t.co/fPGlPow2Lo (Twitter) - Nov 21, 2021
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion date, Trial primary completion date, Metastases: LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) (clinicaltrials.gov) - Nov 19, 2021
P2, N=40, Recruiting, Sponsor: Antonio Fojo
No unexpected serious adverse events developed during prolonged use of lanreotide. Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2023
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): results from the phase 3 SPINET study () - Nov 15, 2021 - Abstract #NANETS2021NANETS_66;
P3
SPINET, the largest prospective study to date with a somatostatin analog in SSTR-positive BP_NETs, suggests LAN 120 mg could be an appropriate treatment option, especially for TC. This study is funded by Ipsen.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, Observational data, Journal: Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland. (Pubmed Central) - Nov 7, 2021
This study is funded by Ipsen. Treatment with lanreotide autogel in a real-world setting showed long-term effectiveness and good tolerability in patients with acromegaly.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system. (Pubmed Central) - Nov 6, 2021
Treatment with lanreotide autogel in a real-world setting showed long-term effectiveness and good tolerability in patients with acromegaly. The study showed that octreotide LAR treatment could be a risk factor in addition to known factors for the development of gastritis in patients with acromegaly.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial completion date, Trial primary completion date, Metastases: Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (clinicaltrials.gov) - Nov 5, 2021
P2, N=6, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
The study showed that octreotide LAR treatment could be a risk factor in addition to known factors for the development of gastritis in patients with acromegaly. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Feb 2022
- ||||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial termination, Metastases: SPINET: Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours (clinicaltrials.gov) - Oct 29, 2021
P3, N=77, Terminated, Sponsor: Ipsen
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Feb 2022 Completed --> Terminated; National Comprehensive Cancer Network & European Neuroendocrine Tumor Society guidelines (2015/2016) led to prescription of somatostatin analogues (SSAs) in this setting, thereby limiting recruitment.
- |||||| Oclaiz (octreotide subcutaneous depot) / Camurus
Enrollment open: SORENTO: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET (clinicaltrials.gov) - Oct 27, 2021
P3, N=300, Recruiting, Sponsor: Camurus AB
Completed --> Terminated; National Comprehensive Cancer Network & European Neuroendocrine Tumor Society guidelines (2015/2016) led to prescription of somatostatin analogues (SSAs) in this setting, thereby limiting recruitment. Not yet recruiting --> Recruiting
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open, Trial primary completion date, Metastases: LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) (clinicaltrials.gov) - Oct 13, 2021
P2, N=40, Recruiting, Sponsor: Antonio Fojo
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: May 2021 --> Dec 2021
- | Keytruda (pembrolizumab) / Merck (MSD), Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion date, Trial primary completion date: PLANET: Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Oct 8, 2021
P1/2, N=22, Active, not recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting | Trial primary completion date: May 2021 --> Dec 2021 Trial completion date: Sep 2021 --> Jun 2022 | Trial primary completion date: Sep 2021 --> May 2021
- |||||||||| Oclaiz (octreotide subcutaneous depot) / Camurus
New P3 trial: SORENTO: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET (clinicaltrials.gov) - Sep 20, 2021
P3, N=300, Not yet recruiting, Sponsor: Camurus AB
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
New P1/2 trial, Metastases: Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Sep 16, 2021
P1/2, N=49, Not yet recruiting, Sponsor: National Health Research Institutes, Taiwan
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study (Channel 3) - Jul 22, 2021 - Abstract #ESMO2021ESMO_1116;
P3
Trial completion date: Sep 2021 --> Jun 2022 | Trial primary completion date: Sep 2021 --> May 2021 SPINET, the largest prospective study to date with a SSA in SSTR-positive BP-NETs, suggests that LAN 120 mg could be an appropriate treatment option, especially for TC.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Review, Journal: Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. (Pubmed Central) - Jul 14, 2021
Despite widespread use of octreotide LAR, several key challenges exist with the current depot-based treatment paradigm...The purpose of this review is to explore all these issues and to re-establish a rationale for the IR formulation, particularly with respect to novel use cases and its use during the COVID-19 pandemic. IMPLICATIONS FOR PRACTICE: There is a need to re-evaluate the role of IR octreotide in combination with depot therapy to provide consistent bioavailability and better control of carcinoid syndrome symptoms.
- | cimdelirsen (IONIS-GHR-LRx) / Ionis
Enrollment closed: Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands (clinicaltrials.gov) - Jul 12, 2021
P2, N=39, Active, not recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
IMPLICATIONS FOR PRACTICE: There is a need to re-evaluate the role of IR octreotide in combination with depot therapy to provide consistent bioavailability and better control of carcinoid syndrome symptoms. Enrolling by invitation --> Active, not recruiting
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, Journal: Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. (Pubmed Central) - Jul 10, 2021
P3
Enrolling by invitation --> Active, not recruiting This study provides new evidence on the long-term safety profile and sustained anti-tumour effects of lanreotide autogel/depot in indolent and progressive metastatic intestinal or pancreatic NETs.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, Journal: Benefits of a nurse-led home injection service for acromegaly patients treated with somatuline autogel. (Pubmed Central) - Jul 10, 2021
A nurse-led home injection service for somatuline autogel injections is associated with high adherence to treatment. Establishing such a program globally may lead to better adherence to treatment and improved disease control.
- | Keytruda (pembrolizumab) / Merck (MSD), Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion date, Trial primary completion date: PLANET: Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Jul 2, 2021
P1/2, N=22, Active, not recruiting, Sponsor: Duke University
Establishing such a program globally may lead to better adherence to treatment and improved disease control. Trial completion date: Jun 2021 --> Sep 2021 | Trial primary completion date: Jun 2021 --> Sep 2021
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, Journal: GHRH secretion from a pancreatic neuroendocrine tumor causing gigantism in a patient with MEN1. (Pubmed Central) - Jun 23, 2021
Lanreotide-Autogel 120 mg/month reduced GHRH by 45% and IGF-1 by 20%...It is important to note that the vast majority of GHRH-secreting tumours (lung, pancreas, phaeochromocytoma) are expected to be visible on cross-sectional imaging (median diameter 55 mm) (1). Therefore, we suggest that a chest X-ray and an abdominal ultrasound checking the adrenal glands and the pancreas should be included in the routine work-up of newly diagnosed acromegaly patients.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Journal: Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms. (Pubmed Central) - Jun 22, 2021
Therefore, we suggest that a chest X-ray and an abdominal ultrasound checking the adrenal glands and the pancreas should be included in the routine work-up of newly diagnosed acromegaly patients. The current study showed that, of many evaluated variables, only the tumour grade was predictive of PFS duration and this should be considered during patient selection for treatment.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Journal: Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly. (Pubmed Central) - Jun 22, 2021
P=N/A
Treatment satisfaction and adherence were good. These findings support use of extended dosing intervals in patients who have achieved good biochemical control with long-acting SSAs.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, Journal: Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg With Prolonged Administration in Indolent Neuroendocrine Tumors. (Pubmed Central) - Jun 22, 2021
A novel method of analysis was used to examine data from the CLARINET trial, confirming LAN is effective at slowing tumor growth and extending progression-free survival (PFS). By providing the expected rate and doubling time of tumor growth early in the course of treatment, this method of analysis has the potential to guide physicians in their management of patients with NETs.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open, Metastases: PALACE: Study to Assess the Efficacy and Safety of Lanreotide Autogel (clinicaltrials.gov) - Jun 21, 2021
P3, N=43, Recruiting, Sponsor: Ipsen
By providing the expected rate and doubling time of tumor growth early in the course of treatment, this method of analysis has the potential to guide physicians in their management of patients with NETs. Not yet recruiting --> Recruiting
- |||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial termination, Metastases: Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. (clinicaltrials.gov) - Jun 14, 2021
P=N/A, N=54, Terminated, Sponsor: Ipsen
Not yet recruiting --> Recruiting Completed --> Terminated; Low enrollment
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: The MetNET-2 Trial (clinicaltrials.gov) - Jun 7, 2021
P1, N=20, Active, not recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Completed --> Terminated; Low enrollment Recruiting --> Active, not recruiting | Trial completion date: Apr 2022 --> Dec 2021 | Trial primary completion date: Apr 2022 --> Dec 2021
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open, HEOR: PREF-NET: United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting (clinicaltrials.gov) - May 27, 2021
P=N/A, N=120, Recruiting, Sponsor: Ipsen
Recruiting --> Active, not recruiting | Trial completion date: Apr 2022 --> Dec 2021 | Trial primary completion date: Apr 2022 --> Dec 2021 Not yet recruiting --> Recruiting
- ||| cimdelirsen (IONIS-GHR-LRx) / Ionis
Enrollment change: Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands (clinicaltrials.gov) - May 19, 2021
P2, N=39, Enrolling by invitation, Sponsor: Ionis Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting N=60 --> 39
- | Lutathera (lutetium Lu 177 dotatate) / Novartis, Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Retrospective data, Journal: Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice. (Pubmed Central) - May 15, 2021
P=N/A
Despite the major recruitment shortfall for the PRELUDE study, effectiveness data were encouraging in this selected population, highlighting the potential usefulness and feasibility of LAN combined with and after PRRT in patients with GEP-NETs. The study also identified challenges associated with evaluating clinical practice in a rare-disease setting and highlighted the need for standardisation of PRRT procedures.
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion, Metastases: Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. (clinicaltrials.gov) - May 12, 2021
P=N/A, N=54, Completed, Sponsor: Ipsen
The study also identified challenges associated with evaluating clinical practice in a rare-disease setting and highlighted the need for standardisation of PRRT procedures. Active, not recruiting --> Completed
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial completion date, Trial primary completion date, Metastases: Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (clinicaltrials.gov) - Apr 28, 2021
P2, N=6, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Completed Trial completion date: May 2021 --> Dec 2021 | Trial primary completion date: May 2021 --> Sep 2021
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (clinicaltrials.gov) - Apr 21, 2021
P4, N=53, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: May 2021 --> Dec 2021 | Trial primary completion date: May 2021 --> Sep 2021 Recruiting --> Active, not recruiting | Trial completion date: Sep 2021 --> Sep 2023 | Trial primary completion date: Sep 2021 --> Sep 2023
- |||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P3 trial, Metastases: PALACE: Study to Assess the Efficacy and Safety of Lanreotide Autogel (clinicaltrials.gov) - Apr 20, 2021
P3, N=43, Not yet recruiting, Sponsor: Ipsen
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, Review, Journal: Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review. (Pubmed Central) - Apr 15, 2021
The findings of this SLR provide a basis that could inform development of decision-making criteria, with patient and HCP treatment perspectives considered. Future studies should utilize a common method to report preference and associated drivers.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. (clinicaltrials.gov) - Apr 12, 2021
P=N/A, N=54, Active, not recruiting, Sponsor: Ipsen
Future studies should utilize a common method to report preference and associated drivers. Recruiting --> Active, not recruiting | N=196 --> 54 | Trial completion date: Jan 2023 --> Apr 2021 | Trial primary completion date: Jan 2023 --> Apr 2021
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
[VIRTUAL] Cost-Minimization Analysis of Lanreotide Autogel Versus Octreotide LAR in Patients with Acromegaly in the Brazilian Public Health System () - Apr 12, 2021 - Abstract #ISPOR2021ISPOR_1152;
CONCLUSIONS : In this model, the estimated cost of treating patients with acromegaly is less with LAN than with octreotide LAR. Savings are achieved due to lower direct acquisition costs, administration of LAN is faster, which reduces the nursing cost, and because the wastage is minimal as LAN has no risk of clogging, compared with octreotide LAR.